The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low

A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents seve...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of leprosy and other mycobacterial diseases Vol. 72; no. 4; p. 493
Main Authors:	Gelber, Robert H, Balagon, Victoria F, Cellona, Roland V
Format:	Journal Article
Language:	English
Published:	United States 01-12-2004
Subjects:	Drug Therapy, Combination Follow-Up Studies Humans Leprostatic Agents - therapeutic use Leprosy Leprosy, Borderline - drug therapy Leprosy, Borderline - epidemiology Leprosy, Borderline - prevention & control Leprosy, Lepromatous - drug therapy Leprosy, Lepromatous - epidemiology Leprosy, Lepromatous - prevention & control Mycobacterium leprae Philippines Recurrence Risk Factors Treatment Failure World Health Organization Philippines
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents several important issues: the need to identify those at risk and the operational requirements needed for their long term follow-up. Also, this group of patients might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.
ISSN:	0148-916X
DOI:	10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO;2